IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
This study has been completed.
Sponsor:
Eli Lilly and Company
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00034619
First received: May 1, 2002
Last updated: July 18, 2006
Last verified: July 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
| Condition | Intervention | Phase |
|---|---|---|
| Colorectal Cancer | Drug: ALIMTA Drug: Oxaliplatin | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Eli Lilly and Company:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of primary cancer of the colon or rectum
- Must have measurable disease
- Must be able to comply with study procedure
Exclusion Criteria:
- Prior chemotherapy for advanced disease
- Pregnancy or lactation
- Candidates for surgical resection of one or more metastatic foci
- Second primary cancer
- Inability to take folic acid or vitamin B12
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00034619
Please refer to this study by its ClinicalTrials.gov identifier: NCT00034619
Locations
| United States, Alabama | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Huntsville, Alabama, United States | |
| United States, Massachusetts | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Pittsfield, Massachusetts, United States | |
| United States, Michigan | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Kalamazoo, Michigan, United States | |
| United States, New York | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Latham, New York, United States | |
| United States, North Carolina | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Asheville, North Carolina, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Goldsboro, North Carolina, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Hendersonville, North Carolina, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Winston-Salem, North Carolina, United States | |
| United States, Ohio | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Columbus, Ohio, United States | |
| United States, Oregon | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Bend, Oregon, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Portland, Oregon, United States | |
| United States, Pennsylvania | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Philadelphia, Pennsylvania, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Pittsburgh, Pennsylvania, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Reading, Pennsylvania, United States | |
| United States, South Carolina | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Charleston, South Carolina, United States | |
| United States, Utah | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Ivins, Utah, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Ogden, Utah, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Provo, Utah, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| St. George, Utah, United States | |
| United States, Washington | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Bellevue, Washington, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Seattle, Washington, United States | |
| "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" | |
| Spokane, Washington, United States | |
Sponsors and Collaborators
Eli Lilly and Company
More Information
| ClinicalTrials.gov Identifier: | NCT00034619 History of Changes |
| Other Study ID Numbers: |
5142 H3E-MC-JMEP |
| Study First Received: | May 1, 2002 |
| Last Updated: | July 18, 2006 |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases |
Intestinal Diseases Rectal Diseases Oxaliplatin Pemetrexed Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |
ClinicalTrials.gov processed this record on September 21, 2017